JP2005512961A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005512961A5 JP2005512961A5 JP2003528538A JP2003528538A JP2005512961A5 JP 2005512961 A5 JP2005512961 A5 JP 2005512961A5 JP 2003528538 A JP2003528538 A JP 2003528538A JP 2003528538 A JP2003528538 A JP 2003528538A JP 2005512961 A5 JP2005512961 A5 JP 2005512961A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- use according
- formula
- sensitizer
- combination therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 17
- 238000000034 method Methods 0.000 claims 15
- 238000002648 combination therapy Methods 0.000 claims 13
- 239000002246 antineoplastic agent Substances 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 11
- 238000011282 treatment Methods 0.000 claims 10
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 9
- 102000003964 Histone deacetylase Human genes 0.000 claims 8
- 108090000353 Histone deacetylase Proteins 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 6
- 230000001939 inductive effect Effects 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 230000000259 anti-tumor effect Effects 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 238000002560 therapeutic procedure Methods 0.000 claims 5
- 230000004069 differentiation Effects 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 238000009169 immunotherapy Methods 0.000 claims 4
- 238000005259 measurement Methods 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 102000006947 Histones Human genes 0.000 claims 3
- 108010033040 Histones Proteins 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 229930003316 Vitamin D Natural products 0.000 claims 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 2
- 230000021736 acetylation Effects 0.000 claims 2
- 238000006640 acetylation reaction Methods 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 230000024245 cell differentiation Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 238000002405 diagnostic procedure Methods 0.000 claims 2
- 238000009396 hybridization Methods 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000011275 oncology therapy Methods 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 239000011710 vitamin D Substances 0.000 claims 2
- 235000019166 vitamin D Nutrition 0.000 claims 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 2
- 229940046008 vitamin d Drugs 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 108091060211 Expressed sequence tag Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 101000654471 Mus musculus NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000007660 Residual Neoplasm Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 238000011122 anti-angiogenic therapy Methods 0.000 claims 1
- 238000011394 anticancer treatment Methods 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000003145 cytotoxic factor Substances 0.000 claims 1
- 230000006196 deacetylation Effects 0.000 claims 1
- 238000003381 deacetylation reaction Methods 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 238000005516 engineering process Methods 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 102000015694 estrogen receptors Human genes 0.000 claims 1
- 108010038795 estrogen receptors Proteins 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 238000003752 polymerase chain reaction Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000021419 recognition of apoptotic cell Effects 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000011199 transformed cell apoptotic process Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 229960000604 valproic acid Drugs 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01121722.1 | 2001-09-18 | ||
| EP01121722A EP1293205A1 (en) | 2001-09-18 | 2001-09-18 | Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease |
| PCT/EP2002/010419 WO2003024442A2 (en) | 2001-09-18 | 2002-09-17 | Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005512961A JP2005512961A (ja) | 2005-05-12 |
| JP2005512961A5 true JP2005512961A5 (https=) | 2005-12-22 |
Family
ID=8178602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003528538A Pending JP2005512961A (ja) | 2001-09-18 | 2002-09-17 | ヒト癌の組合せ療法的処置、及び腫瘍転移並びに微小残存病変処置のためのバルプロ酸及びその誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20050038113A1 (https=) |
| EP (4) | EP1293205A1 (https=) |
| JP (1) | JP2005512961A (https=) |
| AT (1) | ATE314063T1 (https=) |
| AU (1) | AU2002338716B2 (https=) |
| CA (1) | CA2460713A1 (https=) |
| CY (1) | CY1105552T1 (https=) |
| DE (1) | DE60208397T2 (https=) |
| DK (1) | DK1427403T3 (https=) |
| ES (1) | ES2252519T3 (https=) |
| WO (1) | WO2003024442A2 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7250514B1 (en) | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| CA2518318A1 (en) | 2003-03-17 | 2004-09-30 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| CN1791396A (zh) * | 2003-05-21 | 2006-06-21 | 诺瓦提斯公司 | 组蛋白脱乙酰基酶抑制剂与化疗剂的组合 |
| EP1491188A1 (en) * | 2003-06-25 | 2004-12-29 | G2M Cancer Drugs AG | Topical use of valproic acid for the prevention or treatment of skin disorders |
| CA2535889A1 (en) * | 2003-08-29 | 2005-03-17 | Aton Pharma, Inc. | Combination methods of treating cancer |
| WO2005065681A1 (en) * | 2003-12-19 | 2005-07-21 | Takeda San Diego, Inc. | N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer |
| US20050137234A1 (en) * | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
| US7951780B2 (en) * | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
| JP2008524246A (ja) | 2004-12-16 | 2008-07-10 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| NZ589276A (en) | 2005-02-03 | 2012-06-29 | Topotarget Uk Ltd | Combination therapies using hdac inhibitors and erlotinib (tarceva) |
| US7869590B2 (en) * | 2005-04-12 | 2011-01-11 | Broadcom Corporation | Method and system for hardware accelerator for implementing f9 integrity algorithm in WCDMA compliant handsets |
| US7642253B2 (en) | 2005-05-11 | 2010-01-05 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| CN101189003B (zh) | 2005-05-13 | 2012-02-08 | 托波塔吉特英国有限公司 | Hdac抑制剂的药物制剂 |
| EA200800321A1 (ru) | 2005-07-14 | 2008-06-30 | Такеда Сан Диего, Инк. | Ингибиторы гистондеацетилазы |
| JP5377968B2 (ja) | 2005-11-10 | 2013-12-25 | トポターゲット ユーケー リミテッド | 癌治療のために単独で用いるまたは化学療法薬と併用するヒストンデアセチラーゼ（ｈｄａｃ）阻害剤 |
| WO2007075077A1 (es) * | 2005-11-16 | 2007-07-05 | Universidad Nacional Autonoma De Mexico | Uso de agentes modificantes del transcriptoma más quimioterapia o radioterapia contra el cáncer |
| RU2389484C2 (ru) * | 2005-11-18 | 2010-05-20 | Универсидад Насиональ Аутонома Де Мексико | Применение модифицирующих транскриптом агентов и химиотерапии или радиотерапии против рака |
| WO2007084390A2 (en) * | 2006-01-13 | 2007-07-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| JP5113038B2 (ja) * | 2006-03-23 | 2013-01-09 | テムリック株式会社 | 癌治療用キットおよび癌治療用医薬組成物 |
| WO2007145704A2 (en) | 2006-04-24 | 2007-12-21 | Gloucester Pharmaceuticals | Gemcitabine combination therapy |
| DE102006022877B4 (de) * | 2006-05-15 | 2009-01-29 | Sartorius Stedim Biotech Gmbh | Verfahren zur Bestimmung der Viabilität von Zellen in Zellkulturen |
| US8957027B2 (en) | 2006-06-08 | 2015-02-17 | Celgene Corporation | Deacetylase inhibitor therapy |
| EP2056808A4 (en) * | 2006-08-28 | 2009-12-23 | Univ California | Small molecule potentiator of hormonal therapy for breast cancer |
| CA2671649A1 (en) * | 2006-12-06 | 2008-06-12 | Sapporo Medical University | Potentiation of cellular immunity using histone deacetylase (hdac) inhibitors |
| GB0625283D0 (en) * | 2006-12-19 | 2007-01-24 | Cyclacel Ltd | Combination |
| WO2008083288A2 (en) | 2006-12-29 | 2008-07-10 | Gloucester Pharmaceuticals | Purifiction of romidepsin |
| EP2167090A4 (en) * | 2007-06-06 | 2010-08-25 | Univ Maryland | HDAC INHIBITORS AND HORMONE TREATMENT MEDICAMENTS |
| JP2010540426A (ja) | 2007-09-25 | 2010-12-24 | トポターゲット ユーケー リミテッド | 特定のヒドロキサム酸化合物の合成方法 |
| WO2010064422A1 (ja) * | 2008-12-02 | 2010-06-10 | 静岡県公立大学法人 | ヒストン高アセチル化状態における光増感処理による腫瘍殺傷法 |
| US8491927B2 (en) | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
| SG10201505475XA (en) | 2010-07-12 | 2015-09-29 | Celgene Corp | Romidepsin solid forms and uses thereof |
| US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
| KR101733189B1 (ko) * | 2010-10-06 | 2017-05-08 | (주)아모레퍼시픽 | 손톱 또는 발톱 성장 촉진용 조성물 |
| PL2688572T3 (pl) | 2011-03-21 | 2017-08-31 | Valcuria Ab | Kompozycja farmaceutyczna zawierająca inhibitor hdac i steroid oraz jej stosowanie |
| AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
| AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
| NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
| JP6551963B2 (ja) * | 2014-05-14 | 2019-07-31 | 国立大学法人京都大学 | 巨核球前駆細胞の製造方法 |
| CN106794175B (zh) * | 2014-06-12 | 2020-06-09 | 西达-赛奈医疗中心 | 用于治疗癌症的组合物 |
| GB202102606D0 (en) * | 2021-02-24 | 2021-04-07 | Univ Oxford Innovation Ltd | Treatment of ovarian cancer minimal residual disease |
| WO2023008459A1 (ja) * | 2021-07-27 | 2023-02-02 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935450A (en) * | 1982-09-17 | 1990-06-19 | Therapeutical Systems Corporation | Cancer therapy system for effecting oncolysis of malignant neoplasms |
| CA1339034C (en) * | 1988-08-22 | 1997-04-01 | Paul A. Tremblay | Platinum complexes of single isomer neoalkyl acids |
| JPH0279969A (ja) * | 1988-09-19 | 1990-03-20 | Shigeyoshi Fujimoto | 細胞障害性ｔ細胞誘導及び活性化の方法 |
| FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
| DK0632008T3 (da) * | 1993-06-01 | 1998-09-23 | Ono Pharmaceutical Co | Pentansyrederivater |
| US6300373B1 (en) * | 1993-09-10 | 2001-10-09 | American Biogenetic Sciences, Inc. | Antiproliferative and neurotrophic molecules |
| US5672746A (en) * | 1994-08-30 | 1997-09-30 | American Biogenetic Sciences, Inc. | Antiproliferative and neurotrophic molecules |
| US5786344A (en) * | 1994-07-05 | 1998-07-28 | Arch Development Corporation | Camptothecin drug combinations and methods with reduced side effects |
| CN1237909A (zh) * | 1996-10-11 | 1999-12-08 | 加利福尼亚大学董事会 | 联合使用肿瘤细胞与混合淋巴细胞的癌症免疫治疗 |
| US6043389A (en) * | 1997-03-11 | 2000-03-28 | Mor Research Applications, Ltd. | Hydroxy and ether-containing oxyalkylene esters and uses thereof |
| US5939455A (en) * | 1997-03-11 | 1999-08-17 | Beacon Laboratories, Inc. | Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives |
| US6110955A (en) * | 1997-03-11 | 2000-08-29 | Beacon Laboratories, Inc. | Metabolically stabilized oxyalkylene esters and uses thereof |
| US6124495A (en) * | 1997-03-11 | 2000-09-26 | Beacon Laboratories, Inc. | Unsaturated oxyalkylene esters and uses thereof |
| US6110970A (en) * | 1997-03-11 | 2000-08-29 | Beacon Laboratories, Inc. | Nitrogen-containing oxyalkylene esters and uses thereof |
| US6028102A (en) * | 1998-02-24 | 2000-02-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Anticonvulsant drugs and pharmaceutical compositions thereof |
| EP1244461A2 (en) * | 1999-12-23 | 2002-10-02 | The Ontario Cancer Institute | INHIBITION OF GSK-3$g(b) |
| EP1170008A1 (en) * | 2000-07-07 | 2002-01-09 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Valproic acid and derivatives thereof as histone deacetylase inhibitors |
-
2001
- 2001-09-18 EP EP01121722A patent/EP1293205A1/en not_active Withdrawn
-
2002
- 2002-09-17 AT AT02777129T patent/ATE314063T1/de active
- 2002-09-17 ES ES02777129T patent/ES2252519T3/es not_active Expired - Lifetime
- 2002-09-17 CA CA002460713A patent/CA2460713A1/en not_active Abandoned
- 2002-09-17 EP EP05101081A patent/EP1529527A3/en not_active Withdrawn
- 2002-09-17 EP EP02777129A patent/EP1427403B8/en not_active Expired - Lifetime
- 2002-09-17 US US10/489,770 patent/US20050038113A1/en not_active Abandoned
- 2002-09-17 WO PCT/EP2002/010419 patent/WO2003024442A2/en not_active Ceased
- 2002-09-17 AU AU2002338716A patent/AU2002338716B2/en not_active Ceased
- 2002-09-17 DK DK02777129T patent/DK1427403T3/da active
- 2002-09-17 EP EP05019659A patent/EP1602371A3/en not_active Withdrawn
- 2002-09-17 DE DE60208397T patent/DE60208397T2/de not_active Expired - Lifetime
- 2002-09-17 JP JP2003528538A patent/JP2005512961A/ja active Pending
-
2006
- 2006-02-28 CY CY20061100277T patent/CY1105552T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005512961A5 (https=) | ||
| JP7401710B2 (ja) | 正規化バイオマーカースコアからがん治療を特定するためのシステム及び方法 | |
| Jiang et al. | TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis | |
| Gao et al. | Targeting ubiquitin specific proteases (USPs) in cancer immunotherapy: from basic research to preclinical application | |
| Jin et al. | The updated landscape of tumor microenvironment and drug repurposing | |
| Versluis et al. | Learning from clinical trials of neoadjuvant checkpoint blockade | |
| Sharma et al. | Targeting CXCR2 enhances chemotherapeutic response, inhibits mammary tumor growth, angiogenesis, and lung metastasis | |
| Bouchekioua et al. | JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma | |
| Najem et al. | STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma | |
| JP2021502342A (ja) | 癌処置のためのアデノシン経路阻害剤 | |
| Liu et al. | Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models | |
| JP2022500479A (ja) | Ｃｄｃ７阻害剤を含む癌の治療方法 | |
| Guo et al. | Nuclear receptor coactivator SRC-1 promotes colorectal cancer progression through enhancing GLI2-mediated Hedgehog signaling | |
| Jiang et al. | Glycolysis regulation in tumor‐associated macrophages: Its role in tumor development and cancer treatment | |
| Wu et al. | Combination of FAK inhibitor and cytokine-induced killer cell therapy: An alternative therapeutic strategy for patients with triple-negative breast cancer | |
| JP2026053561A (ja) | 循環からミトコンドリアｄｎａ又はゲノムｄｎａを枯渇させることにより疾患及び症状を治療する組成物及び方法 | |
| Fu et al. | Development of granzyme B-targeted smart positron emission tomography probes for monitoring tumor early response to immunotherapy | |
| Ramezani et al. | Current Understanding of the Exosomes and Their Associated Biomolecules in the Glioblastoma Biology, Clinical Treatment, and Diagnosis | |
| Wu et al. | Naringenin: A potential therapeutic agent for modulating angiogenesis and immune response in hepatocellular carcinoma | |
| CN109789155A (zh) | 含有地西他滨、5-氮杂胞苷和四氢尿苷的组合物以及其用途 | |
| JP2025003730A (ja) | 癌患者への免疫チェックポイント阻害薬の投与の有効性を予測するためのデータを収集する方法 | |
| US20190234952A1 (en) | Methods of detecting hypoxia-associate peptides | |
| Arab et al. | An overview of current therapeutic strategies for glioblastoma and the role of CD73 as an alternative curative approach | |
| Cui et al. | Identification of ATM mutation as a potential prognostic biomarker for immune checkpoint inhibitors therapy | |
| Wang et al. | Induced clustering of SHP2-depleted tumor cells in vascular islands restores sensitivity to MEK/ERK inhibition |